 aclaris Therapeutics (NASDAQ:ACRS ) reported third quarter 2018 net revenues of $1.6 million, which consisted of net sales of ESKATA of $0.5 million and contract research revenue of $1.1 million. during the quarter, we also completed the launch of a follow-on offering for approximately $100 million, and closed on a definitive asset purchase agreement with Allergan to acquire worldwide rights to RHOFADE, which is oxymetazoline hydrochloride cream, 1%, for the treatment of common warts or verruca vulgaris. 
 we also completed enrollment in our ongoing open-label studies in alopecia areata, which is the less severe phenotype of the disease. 
 we look forward to providing an update on these 2 topical studies before year-end.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 